» Articles » PMID: 11136936

NXY-059, a Free Radical--trapping Agent, Substantially Lessens the Functional Disability Resulting from Cerebral Ischemia in a Primate Species

Overview
Journal Stroke
Date 2001 Jan 4
PMID 11136936
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: NXY-059 is a novel nitrone with free radical-trapping properties that has a considerable neuroprotective effect in rats. We have now examined the efficacy of this drug at reducing long-term functional disability in a primate model of stroke.

Methods: Twelve monkeys were trained and tested on a variety of behavioral tasks used to dissociate and quantify motor and spatial deficits. Five minutes after permanent occlusion of the right middle cerebral artery, monkeys received a 1-mL intravenous infusion of either saline or NXY-059 (28 mg x kg(-1)), and osmotic minipumps, model 2001D, were implanted subcutaneously to provide continuous drug or saline infusion for 48 hours. Drug-filled pumps released NXY-059 at 16 mg x kg(-1) x h(-1). The monkeys were retested 3 and 10 weeks after surgery to assess functional disability. Surgery, behavioral testing, and histology were all done blinded to treatment condition.

Results: NXY-059-treated monkeys were significantly better at reaching with their hemiparetic arm than were saline-treated monkeys when retested 3 weeks (P:<0.01) and 10 weeks (P:<0.01) after surgery. Drug treatment also significantly lessened the degree of spatial perceptual neglect (P:<0.01), a debilitating though ameliorating consequence of this infarct. NXY-059 treatment reduced the overall amount of brain damage by >50% of saline-treatment values, with similar levels of protection afforded to both white and gray matter.

Conclusions: This novel drug has a substantial protective effect, lessening the disability caused by an experimentally induced stroke in a primate species. These findings provide considerable encouragement for the clinical development of NXY-059.

Citing Articles

The mitochondria as a potential therapeutic target in cerebral I/R injury.

Fang S, Huang W, Qu X, Chai W Front Neurosci. 2025; 18():1500647.

PMID: 39844858 PMC: 11752919. DOI: 10.3389/fnins.2024.1500647.


Comprehensive Assessment of Ischemic Stroke in Nonhuman Primates: Neuroimaging, Behavioral, and Serum Proteomic Analysis.

Li G, Lan L, He T, Tang Z, Liu S, Li Y ACS Chem Neurosci. 2024; 15(7):1548-1559.

PMID: 38527459 PMC: 10996879. DOI: 10.1021/acschemneuro.3c00826.


Pharmacokinetics, Safety Profile, and Tolerability of Tetramethylpyrazine Nitrone Tablets After Single and Multiple Ascending Doses in Healthy Chinese Volunteers.

Zhu G, Wang L, Zhong S, Han S, Peng H, Tong M Eur J Drug Metab Pharmacokinet. 2024; 49(2):207-217.

PMID: 38381348 DOI: 10.1007/s13318-024-00877-5.


Evolving Clinical-Translational Investigations of Cerebroprotection in Ischemic Stroke.

Li Y, Schappell L, Polizu C, DiPersio J, Tsirka S, Halterman M J Clin Med. 2023; 12(21).

PMID: 37959180 PMC: 10649331. DOI: 10.3390/jcm12216715.


A Reliable Nonhuman Primate Model of Ischemic Stroke with Reproducible Infarct Size and Long-term Sensorimotor Deficits.

Lin X, Wang H, Huang S, Chen L, Yang S, Zhao P Aging Dis. 2023; 14(1):245-255.

PMID: 36818571 PMC: 9937702. DOI: 10.14336/AD.2022.0722.